Shanghai Fosun Pharmaceutical (Group) Co (STU:08HH) Issuance of Debt: €1,879 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:08HH Shanghai Fosun Pharmaceutical (Group) Co Ltd STU:08HH
65 GF Score
Price €1.86
GF Value €2.72
Valuation Possible Value Trap
! 10 Warning Signs
View Full Analysis

What is Shanghai Fosun Pharmaceutical (Group) Co Issuance of Debt?

Shanghai Fosun Pharmaceutical (Group) Co STU:08HH +4.12% 65 Issuance of Debt is €1,879 Mil as of Jun. 2026. GuruFocus rates STU:08HH with a GF Score™ of 65/100 and a GF Value™ of €2.72 (Possible Value Trap). The stock has 10 warning signs investors should review.

Shanghai Fosun Pharmaceutical (Group) Co's Issuance of Debt for the six months ended in Jun. 2026 was €0 Mil.

Shanghai Fosun Pharmaceutical (Group) Co's Issuance of Debt for the trailing twelve months (TTM) ended in Jun. 2026 was €1,879 Mil.

Shanghai Fosun Pharmaceutical (Group) Co Issuance of Debt Related Terms

Shanghai Fosun Pharmaceutical (Group) Co Issuance of Debt Historical Data

* Premium members only.

The historical data trend for Shanghai Fosun Pharmaceutical (Group) Co's Issuance of Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shanghai Fosun Pharmaceutical (Group) Co Issuance of Debt Chart

Shanghai Fosun Pharmaceutical (Group) Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Issuance of Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Shanghai Fosun Pharmaceutical (Group) Co Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Issuance of Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
STU:08HH
65GF Score
Shanghai Fosun Pharmaceutical (Group) Co Ltd STU:08HH
Issuance of Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Shanghai Fosun Pharmaceutical (Group) Co Issuance of Debt Calculation

Issuance of Debt represents all the cash inflow from debt, including both long-term debt and short-term debt.

Issuance of Debt for the trailing twelve months (TTM) ended in Jun. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was €1,879 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Issuance of Debt →
What does a Issuance of Debt of €1,879 Mil mean?
Shanghai Fosun Pharmaceutical (Group) Co (STU:08HH) has a Issuance of Debt of €1,879 Mil as of Jun. 2026. Issuance of Debt is all the cash inflow from debt, including both long-term debt and short-term debt. View historical data on Shanghai Fosun Pharmaceutical (Group) Co and its competitors.
Is Shanghai Fosun Pharmaceutical (Group) Co's Issuance of Debt too high?
Shanghai Fosun Pharmaceutical (Group) Co's current Issuance of Debt is €1,879 Mil. Overall, Shanghai Fosun Pharmaceutical (Group) Co has a GF Score™ of 65/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Shanghai Fosun Pharmaceutical (Group) Co's Issuance of Debt compare to ZTS?
Shanghai Fosun Pharmaceutical (Group) Co's Issuance of Debt of €1,879 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Issuance of Debt for a Drug Manufacturers company?
A good Issuance of Debt depends on the Drug Manufacturers industry context. However, Issuance of Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Issuance of Debt mean?
A high Issuance of Debt can signal that a stock is expensive relative to its fundamentals. Issuance of Debt is all the cash inflow from debt, including both long-term debt and short-term debt. View historical data on Shanghai Fosun Pharmaceutical (Group) Co and its competitors. Shanghai Fosun Pharmaceutical (Group) Co's current Issuance of Debt is €1,879 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Fosun Pharmaceutical (Group) Co stock overvalued right now?
Based on GuruFocus' analysis, Shanghai Fosun Pharmaceutical (Group) Co (STU:08HH) is currently considered Possible Value Trap. The stock's GF Value™ is €2.72, compared to a current price of €1.86 — trading 31.7% below its estimated fair value. The current Issuance of Debt is €1,879 Mil. Shanghai Fosun Pharmaceutical (Group) Co's overall GF Score™ is 65/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Issuance of Debt calculated?
Issuance of Debt is calculated from a company's financial statements. For Shanghai Fosun Pharmaceutical (Group) Co (STU:08HH), the current Issuance of Debt is €1,879 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Shanghai Fosun Pharmaceutical (Group) Co (STU:08HH) Overvalued in 2026?

Based on GuruFocus' analysis, Shanghai Fosun Pharmaceutical (Group) Co stock appears to be undervalued. The current stock price of €1.86 is trading 31.7% below its estimated GF Value™ of €2.72. GuruFocus considers Shanghai Fosun Pharmaceutical (Group) Co to be Possible Value Trap.

Key valuation signals for STU:08HH:

  • Issuance of Debt: €1,879 Mil
  • GF Value™: €2.72 vs. price of €1.86 (31.7% below fair value)
  • GF Score™: 65/100 with 10 warning signs

No single metric tells the full story. See the STU:08HH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Shanghai Fosun Pharmaceutical (Group) Co Business Description

Address No. 1289 Yishan Road, Building A, Fosun Technology Park, Shanghai, CHN, 200233
Shanghai Fosun Pharmaceutical (Group) Co Ltd is engaged in the development, manufacture, sale of pharmaceutical products and medical equipment, the import and export of medical equipment, and the provision of related and other consulting services and investment management. Its business segments are Pharmaceutical manufacturing, Healthcare Services, Medical devices, and medical diagnosis. It generates the majority of its revenue from the Pharmaceutical manufacturing segment. The company considers mergers and acquisitions as a potential component of its operational growth for expanding its research, development, manufacturing, and marketing capabilities. Its geographic areas are the Chinese mainland, Regions outside the Chinese mainland, and other countries.
65GF Score

Get the complete analysis for STU:08HH

Issuance of Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.86
Price
€2.72
GF Value